Volume 3.28 | Jul 19

Mesenchymal Cell News 3.28, July 19, 2011
     In this issue: Science News | Current Publications | Industry News | Policy News | Events
Treatment of Human Mesenchymal Stem Cells with Angiotensin Receptor Blocker Improved Efficiency of Cardiomyogenic Transdifferentiation and Improved Cardiac Function via Angiogenesis
In order to improve the modest efficacy of mesenchymal stem cell (MSC) transplantation, the treatment of human MSCs with angiotensin receptor blockers was investigated. [Stem Cells]

Stem Cell Breakthrough Heralds New Era of Therapy Development
Scientists have uncovered a new method for culturing adult stem cells which could lead to the creation of revolutionary stem cell therapies for conditions such as arthritis, Alzheimer’s disease and Parkinson’s disease. [Press release from the University of Glasgow discussing online prepublication in Nature Materials]

ON168-HIV NatureWebcast_645x110
CURRENT PUBLICATIONS (Ranked by Impact Factor of the Journal)

Nanoscale Surfaces for the Long-Term Maintenance of Mesenchymal Stem Cell Phenotype and Multipotency
Researchers identify a nanostructured surface that retains stem-cell phenotype and maintains stem-cell growth over eight weeks. [Nat Mater]

Enhanced Angiogenesis by Transplantation of Mesenchymal Stem Cell Sheet Created by a Novel Magnetic Tissue Engineering Method
In this study, researchers investigated a therapeutic potential of mesenchymal stem cell sheet created by a novel magnetite tissue engineering technology for reparative angiogenesis. [Arterioscler Thromb Vasc Biol]

Mesenchymal Stem Cells Stably Transduced with a Dominant-Negative Inhibitor of CCL2 Greatly Attenuate Bleomycin-Induced Lung Damage
In this study, researchers established mesenchymal stem cells (MSCs) that are stably transduced by a lentiviral vector expressing 7ND, a dominant-negative inhibitor of CCL2, to enhance the therapeutic function of MSCs. [Am J Pathol]

Purinergic Receptors Influence the Differentiation of Human Mesenchymal Stem Cells
Researchers show for the first time that the combination of several P2 receptors plays a role in the differentiation of adult stem cells. [Stem Cells Dev]

Spatial Organization of Mesenchymal Stem Cells In Vitro – Results from a New Individual Cell-Based Model with Podia
Researchers present an individual cell-based model that is able to quantitatively describe the spatio-temporal organization of mesenchymal stem cells in culture. [PLoS One]

Enhanced Mesenchymal Stromal Cell Recruitment via Natural Killer Cells by Incorporation of Inflammatory Signals in Biomaterials
Researchers studied how biomaterials designed to incorporate inflammatory signals affected natural killer (NK) cell behavior and NK cell-mesenchymal stem/stromal cell interactions. [J R Soc Interface]

Posterolateral Spinal Fusion with Nano-Hydroxyapatite-Collagen/PLA Composite and Autologous Adipose-Derived Mesenchymal Stem Cells in a Rabbit Model
In this study, researchers analyzed the effectiveness of a new mineralized collagen matrix, nano-hydroxyapatite–collagen–polylactic acid (PLA), combined with autologous adipose-derived mesenchymal stem cells as a graft material for posterolateral spinal fusion in a rabbit model. [J Tissue Eng Regen Med]

Mesenchymal Stem Cells Rescue the Alzheimer’s Disease Cell Model from Cell Death Induced by Misfolded Truncated Tau
The aim of this study was to test the possible capability of rat mesenchymal stem cells to interfere with human misfolded truncated tau protein-induced cell death. [Neuroscience]

Cocaine- and Amphetamine-Regulated Transcript Promotes the Differentiation of Mouse Bone Marrow-Derived Mesenchymal Stem Cells into Neural Cells
This study demonstrated that cocaine- and amphetamine-regulated transcript could promote the differentiation of bone marrow mesenchymal stromal cells into neural cells through increasing neurofactors, including BNDF and NGF. [BMC Neurosci]


BrainStorm Signs MOU for Collaboration with Massachusetts General Hospital and University of Massachusetts Medical School to Conduct Human Clinical Trials in the United States
BrainStorm Cell Therapeutics Inc. announced that it has entered into a Memorandum of Understating (MOU) with Massachusetts General Hospital and the University of Massachusetts Medical School in anticipation of applying for FDA approval to begin ALS human clinical trials in the United States. [BrainStorm Cell Therapeutics Inc., Press Release]

Cytori Completes Equity Agreement; Funding to Support ADVANCE Clinical Trial & Other Corporate Initiatives
Cytori Therapeutics entered into an equity purchase agreement with Seaside 88, LP. [Cytori Therapeutics Press Release]


National Institutes of Health (United States)

Food and Drug Administration (United States)

Center for Biologics Evaluation and Research (United States)

European Medicines Agency (European Union)

Medicines and Healthcare Products Regulatory Agency (United Kingdom)

Therapeutic Goods Administration (Australia)

NEW Stem Cell Society Singapore Symposium 2011 
November 17-18, 2011 
Singapore, Singapore

Lab Technologist – Tissue Culture (STEMCELL Technologies)

Research and Development Technologist, hPSC Media (STEMCELL Technologies)

Scientist (iPSC) (STEMCELL Technologies)

Postdoctoral Research Fellow (Tshwane University of Technology)

Industrial Postdoctoral Research Fellow – Regenerative Medicine Cell Therapy (Tissue Regeneration Therapeutics Inc.)

Recruit Top Talent
Reach more than 11,000 potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Jobs are categorized regionally:
United States, Canada, Europe, Asia Pacific

Visit here to post your career opportunities.

Have we missed an important article or publication in Mesenchymal Cell News? Click here to submit!

Comments or Suggestions? Email [email protected] with your feedback.

Learn more about Mesenchymal Cell News: Archives | Events | Contact Us